CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Neurocrine Biosciences, Inc. - NBIX CFD

129.38
3.85%
Market Trading Hours* (UTC) Opens on Friday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 1.12
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Neurocrine Biosciences Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 134.56
Open* 132.7
1-Year Change* 29.17%
Day's Range* 129.38 - 133.31
52 wk Range 89.04-139.56
Average Volume (10 days) 743.63K
Average Volume (3 months) 15.26M
Market Cap 13.44B
P/E Ratio 73.13
Shares Outstanding 98.25M
Revenue 1.78B
EPS 1.87
Dividend (Yield %) N/A
Beta 0.25
Next Earnings Date Feb 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 28, 2024 134.56 -0.85 -0.63% 135.41 135.73 133.48
Feb 27, 2024 135.91 1.25 0.93% 134.66 136.45 134.13
Feb 26, 2024 135.47 2.66 2.00% 132.81 135.95 132.81
Feb 23, 2024 134.08 1.19 0.90% 132.89 134.43 131.54
Feb 22, 2024 132.86 2.86 2.20% 130.00 133.67 129.89
Feb 21, 2024 130.45 -1.11 -0.84% 131.56 133.05 129.78
Feb 20, 2024 132.56 -0.36 -0.27% 132.92 133.97 131.30
Feb 16, 2024 131.74 -2.27 -1.69% 134.01 134.24 131.74
Feb 15, 2024 133.92 2.71 2.07% 131.21 134.01 130.92
Feb 14, 2024 131.68 -2.27 -1.69% 133.95 135.17 131.01
Feb 13, 2024 133.37 4.01 3.10% 129.36 134.77 129.36
Feb 12, 2024 130.37 -1.07 -0.81% 131.44 132.94 129.73
Feb 9, 2024 132.14 -1.90 -1.42% 134.04 134.55 131.51
Feb 8, 2024 133.91 -2.46 -1.80% 136.37 136.37 132.34
Feb 7, 2024 136.13 4.27 3.24% 131.86 140.30 126.97
Feb 6, 2024 142.86 1.20 0.85% 141.66 143.02 140.72
Feb 5, 2024 141.52 1.18 0.84% 140.34 141.87 139.41
Feb 2, 2024 141.12 -0.73 -0.51% 141.85 142.75 140.86
Feb 1, 2024 141.97 2.56 1.84% 139.41 142.61 137.86
Jan 31, 2024 139.59 -1.61 -1.14% 141.20 142.08 139.15

Neurocrine Biosciences, Inc. Events

Time (UTC) Country Event
Tuesday, March 5, 2024

Time (UTC)

16:10

Country

US

Event

Neurocrine Biosciences Inc at TD Cowen Health Care Conference
Neurocrine Biosciences Inc at TD Cowen Health Care Conference

Forecast

-

Previous

-
Wednesday, May 1, 2024

Time (UTC)

11:30

Country

US

Event

Q1 2024 Neurocrine Biosciences Inc Earnings Release
Q1 2024 Neurocrine Biosciences Inc Earnings Release

Forecast

-

Previous

-
Thursday, May 16, 2024

Time (UTC)

17:30

Country

US

Event

Neurocrine Biosciences Inc Annual Shareholders Meeting
Neurocrine Biosciences Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1488.7 1133.5 1045.9 788.087 451.24
Revenue 1488.7 1133.5 1045.9 788.087 451.24
Total Operating Expense 1309.7 1031 901.3 715.804 414.345
Selling/General/Admin. Expenses, Total 751 583.3 433.3 354.062 248.932
Research & Development 463.8 328.1 275 200.042 160.524
Operating Income 179 102.5 144.6 72.283 36.895
Interest Income (Expense), Net Non-Operating 34.9 -1.1 -37.9 -25.741 -15.054
Gain (Loss) on Sale of Assets
Other, Net
Net Income Before Taxes 213.9 101.4 106.7 46.542 21.841
Net Income After Taxes 154.5 89.6 407.3 37.012 21.111
Net Income Before Extra. Items 154.5 89.6 407.3 37.012 21.111
Net Income 154.5 89.6 407.3 37.012 21.111
Income Available to Common Excl. Extra. Items 154.5 89.6 407.3 37.012 21.111
Income Available to Common Incl. Extra. Items 154.5 89.6 407.3 37.012 21.111
Diluted Net Income 154.5 89.6 407.3 37.012 21.111
Diluted Weighted Average Shares 98.9 97.9 97.8 95.732 95.386
Diluted EPS Excluding Extraordinary Items 1.56218 0.91522 4.16462 0.38662 0.22132
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS 2.08583 1.86564 5.38021 1.66815 0.22132
Cost of Revenue, Total 23.2 14.3 10.1 7.428 4.889
Gross Profit 1465.5 1119.2 1035.8 780.659 446.351
Unusual Expense (Income) 71.7 105.3 182.9 154.272
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 452.7 420.4 412 387.9 378.2
Revenue 452.7 420.4 412 387.9 378.2
Cost of Revenue, Total 11.5 8.5 7.7 6.1 4.8
Gross Profit 441.2 411.9 404.3 381.8 373.4
Total Operating Expense 379.1 534.6 308.6 300.1 393.5
Selling/General/Admin. Expenses, Total 221.8 242.7 182.9 186.3 182.8
Research & Development 145.8 139.5 118 107.7 135.9
Operating Income 73.6 -114.2 103.4 87.8 -15.3
Interest Income (Expense), Net Non-Operating 48 10.9 14.5 10.1 -8
Net Income Before Taxes 121.6 -103.3 117.9 97.9 -23.3
Net Income After Taxes 95.5 -76.6 89 68.5 -16.9
Net Income Before Extra. Items 95.5 -76.6 89 68.5 -16.9
Net Income 95.5 -76.6 89 68.5 -16.9
Income Available to Common Excl. Extra. Items 95.5 -76.6 89 68.5 -16.9
Income Available to Common Incl. Extra. Items 95.5 -76.6 89 68.5 -16.9
Diluted Net Income 95.5 -76.6 89 68.5 -16.9
Diluted Weighted Average Shares 100.2 97.1 100.7 99 95.6
Diluted EPS Excluding Extraordinary Items 0.95309 -0.78888 0.88381 0.69192 -0.17678
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.95309 0.17441 0.88381 0.69192 0.29916
Unusual Expense (Income) 0 143.9 0 0 70
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1453.5 972.8 1016.2 831.034 737.777
Cash and Short Term Investments 989.3 711.3 801 670.524 650.913
Cash & Equivalents 262.9 340.8 187.1 112.279 141.714
Short Term Investments 726.4 370.5 613.9 558.245 509.199
Other Current Assets, Total 79.1 45.5 30.1 16.647 18.594
Total Assets 2368.7 2072.5 1734.7 1306.04 993.151
Property/Plant/Equipment, Total - Net 145.6 155.8 127.4 116.278 33.869
Property/Plant/Equipment, Total - Gross 211.9 207.7 169.1 149.837 62.14
Accumulated Depreciation, Total -66.3 -51.9 -41.7 -33.559 -28.271
Long Term Investments 401.5 624.4 265.3 355.522 216.028
Other Long Term Assets, Total 330.9 319.5 325.8 3.206 5.477
Total Current Liabilities 537.7 245.8 186.5 565.287 88.233
Accounts Payable 46.214 38.381
Accrued Expenses 129.3 99.5 81.4 72.719 34.41
Notes Payable/Short Term Debt 0 0 0 408.807 0
Other Current Liabilities, Total 3.3 3.5 7.5 37.547 15.442
Total Liabilities 660.9 698.5 608.5 669.117 512.386
Total Long Term Debt 0 335.1 317.9 0 388.496
Other Liabilities, Total 123.2 117.6 104.1 103.83 35.657
Total Equity 1707.8 1374 1126.2 636.923 480.765
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.1 0.1 0.1 0.092 0.091
Additional Paid-In Capital 2122.4 2011.4 1849.7 1768.12 1660.36
Retained Earnings (Accumulated Deficit) -406.8 -635.8 -725.4 -1132.7 -1177.76
Other Equity, Total -7.9 -1.7 1.8 1.413 -1.932
Total Liabilities & Shareholders’ Equity 2368.7 2072.5 1734.7 1306.04 993.151
Total Common Shares Outstanding 96.5 94.9 93.5 92.272 90.797
Total Receivables, Net 350 185.5 157.1 126.575 57.406
Accounts Receivable - Trade, Net 350 185.5 157.1 126.575 57.406
Long Term Debt 0 335.1 317.9 0 388.496
Total Inventory 35.1 30.5 28 17.288 10.864
Payable/Accrued 235.7 142.8 97.6
Intangibles, Net 37.2
Current Port. of LT Debt/Capital Leases 169.4
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 1649.9 1496.6 1432.8 1453.5 1205.5
Cash and Short Term Investments 1095.1 976.7 894.6 989.3 799.4
Cash & Equivalents 293.7 160.2 103.8 262.9 212.2
Short Term Investments 801.4 816.5 790.8 726.4 587.2
Total Receivables, Net 417.8 387.6 391.6 350 301.2
Accounts Receivable - Trade, Net 417.8 387.6 391.6 350 301.2
Total Inventory 28.8 31.7 33.4 35.1 37
Other Current Assets, Total 108.2 100.6 113.2 79.1 67.9
Total Assets 2848.2 2613.1 2359.8 2368.7 2143.4
Property/Plant/Equipment, Total - Net 149.6 149.1 147.2 145.6 150.5
Long Term Investments 587.5 515.6 380.3 401.5 457.5
Other Long Term Assets, Total 426.3 414.9 362.3 330.9 329.9
Total Current Liabilities 691.6 582.5 374.1 537.7 485.1
Payable/Accrued 394.9 391.6 355.7 347.6 297.8
Accrued Expenses 125.9 17.7 17.6 17.4 17.3
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.9 3.5 0.8 3.3 0.8
Total Liabilities 846.1 760.1 675.3 660.9 598.8
Total Long Term Debt 0 0 169.5 0 0
Long Term Debt 169.5 0 0
Other Liabilities, Total 154.5 177.6 131.7 123.2 113.7
Total Equity 2002.1 1853 1684.5 1707.8 1544.6
Preferred Stock - Non Redeemable, Net
Common Stock 0.1 0.1 0.1 0.1 0.1
Additional Paid-In Capital 2308.5 2241.9 2170.5 2122.4 2054.3
Retained Earnings (Accumulated Deficit) -304.8 -387.9 -483.4 -406.8 -495.8
Other Equity, Total -1.7 -1.1 -2.7 -7.9 -14
Total Liabilities & Shareholders’ Equity 2848.2 2613.1 2359.8 2368.7 2143.4
Total Common Shares Outstanding 98.2 97.6 97.5 96.5 96.1
Current Port. of LT Debt/Capital Leases 169.9 169.7 0 169.4 169.2
Intangibles, Net 34.9 36.9 37.2 37.2
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 154.5 89.6 407.3 37.012 21.111
Cash From Operating Activities 339.4 256.5 228.5 152.054 101.364
Cash From Operating Activities 15.1 10.9 8.6 7.452 4.024
Non-Cash Items 217.6 135 161.2 107.349 77.986
Cash Interest Paid 6.6 8.6 11.6 11.644 11.644
Changes in Working Capital -67.4 16.7 -37.9 0.241 -1.757
Cash From Investing Activities -177.1 -130.2 4.1 -211.073 -242.915
Capital Expenditures -16.5 -23.4 -10.9 -14.748 -24.812
Other Investing Cash Flow Items, Total -160.6 -106.8 15 -196.325 -218.103
Cash From Financing Activities -234.3 27.4 -157.8 27.313 29.53
Issuance (Retirement) of Stock, Net 44.7 27.5 29.1 27.313 29.53
Issuance (Retirement) of Debt, Net -279 -0.1 -186.9 0 0
Net Change in Cash -73.3 153.7 74.8 -31.706 -112.021
Cash Taxes Paid 14.4 5.1 15.3 0.507
Deferred Taxes 19.1 4.3 -310.7
Amortization 0.5
Foreign Exchange Effects -1.3
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -76.6 154.5 65.5 -3 13.9
Cash From Operating Activities -125.2 339.4 196.4 97.6 -40.5
Cash From Operating Activities 4.1 15.1 11.2 7.2 3.3
Deferred Taxes -31.6 19.1 5.6 -3.4 -0.3
Non-Cash Items 35.5 217.6 180 147.1 18.3
Changes in Working Capital -57.5 -67.4 -65.9 -50.3 -75.7
Cash From Investing Activities -42.1 -177.1 -61.5 -0.2 -31.6
Capital Expenditures -8.5 -16.5 -14.7 -16.4 -7.6
Other Investing Cash Flow Items, Total -33.6 -160.6 -46.8 16.2 -24
Cash From Financing Activities 8.2 -234.3 -258.9 -270.3 6.1
Issuance (Retirement) of Stock, Net 8.2 44.7 20.1 8.7 6.1
Issuance (Retirement) of Debt, Net -279 -279 -279 0
Net Change in Cash -159.1 -73.3 -124 -172.9 -66
Cash Taxes Paid 0.2 14.4 4.3 3.1
Cash Interest Paid 6.6 4.6 4.6
Amortization 0.9 0.5
Foreign Exchange Effects -1.3
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BlackRock Institutional Trust Company, N.A. Investment Advisor 10.6161 10366912 220306 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.76 9530883 -26814 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.0516 3956499 156584 2023-06-30 LOW
Bellevue Asset Management AG Investment Advisor 2.6756 2612800 -500 2023-06-30 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 1.9547 1908844 -85677 2023-06-30 LOW
Armistice Capital LLC Hedge Fund 1.6897 1650000 58000 2023-06-30 MED
Renaissance Technologies LLC Hedge Fund 1.6829 1643402 -303662 2023-06-30 HIGH
JP Morgan Asset Management Investment Advisor 1.6353 1596880 -54369 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.56 1523408 87671 2023-06-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 1.4331 1399439 228393 2023-06-30 LOW
Citadel Advisors LLC Hedge Fund 1.3377 1306273 831881 2023-06-30 LOW
Rock Springs Capital Management LP Hedge Fund 1.3103 1279500 69400 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 1.2666 1236839 -61520 2023-06-30 LOW
Deerfield Management Company, L.P. Hedge Fund 1.2388 1209714 -535000 2023-06-30 MED
Amundi Asset Management, SAS Investment Advisor/Hedge Fund 1.2186 1190026 -30338 2023-06-30 LOW
Woodline Partners LP Hedge Fund 1.1799 1152189 753495 2023-06-30 HIGH
American Century Investment Management, Inc. Investment Advisor/Hedge Fund 1.1308 1104267 242362 2023-06-30 LOW
Brown Advisory Investment Advisor/Hedge Fund 1.1158 1089582 -10274 2023-09-30 LOW
DSM Capital Partners, LLC Investment Advisor 1.0858 1060270 -199261 2023-06-30 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 1.016 992153 -119041 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Neurocrine Company profile

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Neurocrine Biosciences, Inc. revenues increased 8% to $1.13B. Net income decreased 78% to $89.6M. Revenues reflect Net product sales increase of 10% to $1.09B. Net income was offset by General and administrative -others increase of 36% to $497.5M (expense), Research and development - others increase of 16% to $279.7M (expense).

Equity composition

Common Stock $.001 Par, 04/11, 110M auth. 55,200,641 issd. Insiders own 1.73%. IPO: 5/96, 4,394,286 shares (1,214,286 by the Company) @ $10.50 by Robertson, Stephens & Co. LLC. PO: 12/00, 3M shares @ $30 by Robertson Stephens. PO 12/01, 3.5M shares @ $46.75 by Deutsche Banc Alex. Brown. FY'00 Q's are restated.

Industry: Bio Therapeutic Drugs

12780 El Camino Real
SAN DIEGO
CALIFORNIA 92130-2042
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

BTC/USD

61,517.05 Price
+1.330% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,043.82 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0195%
Short position overnight fee 0.0112%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.60 Price
+3.440% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

78.25 Price
+0.190% 1D Chg, %
Long position overnight fee 0.0264%
Short position overnight fee -0.0483%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading